Challenge trials may increase in coming years as new and improved challenge agents better emulate “natural” disease states.
Adrian Wildfire
Advertisement
Adrian Wildfire is project director, Infectious Diseases &Viral Challenge Unit, SGS Life SciencesâClinical Research.
Articles by Adrian Wildfire
Advertisement
Latest Updated Articles
Using Human Challenge Trials to Develop Flu VaccinesNovember 15th 2017
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
3
AstraZeneca Acquires Omniose, Adding Bioconjugate Vaccine Platform
4
The BioPharm Brief: Base Editing Hits Its Mark in Sickle Cell, a Phase 3 Win in Sjögren’s, and Off-the-Shelf CAR-T in Lupus
5